Our Recommendations
- Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung (2022)
- Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [recombinant] contre la COVID-19 (vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII) (2021)
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) (2022)
- Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2 (2021)
New Publications
- AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (2021)
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
- Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (2021)
- Oxford–AstraZeneca COVID-19 vaccine efficacy (2021)
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) (2022)
Filter
26
Featured
Recommendations
6
Language
Document type
Fact sheets
14
Guidelines
6
Studies & Reports
4
Manuals
1
Situation Updates
1
Countries / Regions
West and Central Africa
3
East and Southern Africa
3
India
3
Germany
2
Brazil
2
South Sudan
2
Western and Central Europe
1
South Korea
1
Authors & Publishers
Publication Years
Category
COVID-19
12
Guidelines
2
Policies
1
Toolboxes
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
AstraZeneca-SKBio in South Korea and Serum Institute of India
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
